Leerink Partners trimmed its Q2 2025 earnings estimate for Eli Lilly to $5.40 per share, down from $5.54. Several firms ...

Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly ...

Lilly Tino, the transgender influencer and TikTok content creator, well-known for her transition, discussing trans issues, and often posting controversial content online, announced that she was steppi ...

The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

Abbott Laboratories is a dividend growth machine that's known for consistency. AbbVie's dividend has more than quadrupled ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...